Because VEGFR2 signaling is mainly responsible for the pro-angiogenic effect of VEGF-A1, a concerted effort has been made to block VEGF-A signaling through the use of monoclonal antibodies (bevacizumab) and tyrosine kinase inhibitors (such as sunitinib and sorafenib) in cancer therapy3. The gene discussed is VEGFA; the disease is cancer.